Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Tacrolimus: a further update of its use in the management of organ transplantation.
The reduced incidence of rejection episodes in renal transplant recipients receiving tacrolimus translated into a better cost effectiveness relative to cyclosporin microemulsion treatment, which was reflected in improved cost effectiveness. Expand
Propofol: a review of its use in intensive care sedation of adults.
Emergence from sedation is more rapid with propofol than with midazolam, even after long-term administration, which enables better control of the depth of sedation in response to titration and more predictable recovery times. Expand
Amisulpride: a review of its use in the management of schizophrenia.
Oral amisulpride is an effective and well tolerated option for the first-line treatment of patients with acute schizophrenia as well as for those requiring long-term maintenance therapy and does not seem to be associated with diabetogenic effects. Expand
Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
Intravenous trastuzumab is effective as a single-agent, and in combination with chemotherapy it significantly improves the median time to disease progression and survival time in patients with metastatic breast cancer overexpressing the HER2 receptor compared with chemotherapy alone. Expand
AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)
The AS04-adjuvanted HPV 16/18 vaccine elicits a high immunogenic response and is highly protective against cervical intraepithelial neoplasia and infection causally related to high-risk oncogenic HPV types, thereby reducing the burden of premalignant cervical lesions and, very likely, cervical cancer. Expand
Basiliximab: a review of its use as induction therapy in renal transplantation.
Initial results indicate that induction with basiliximab is associated with a higher rate of biopsy-proven acute rejection than alemtuzumab induction, and provides an effective, well tolerated option for the prophylaxis of acute renal transplant rejection. Expand
Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
Octreotide long-acting release is a somatostatin analogue designed for once monthly intramuscular injection that effectively controls GH and IGF-1 secretion in about 55-70% of patients with acromegaly, and is generally well tolerated by most patients. Expand
Phentermine and Topiramate Extended Release (Qsymia™)
The milestones in the development of phentermine/topiramate ER leading to this first approval for obesity are summarized. Expand
Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.
- K. McKeage
- 30 July 2012
Docetaxel every 3 weeks plus continuous prednisone remains the optimum first-line chemotherapy for most patients with advanced CRPC until such time that ongoing research with docetaxe and emerging therapeutic agents can demonstrate improved survival. Expand
Doxycycline 40 mg Capsules (30 mg Immediate-Release/10 mg Delayed-Release Beads)
Maximum anti-inflammatory efficacy appears to be achieved with doxycycline 40 mg capsules once daily, as no additional improvement in rosacea symptoms was achieved with oral doxy cycline 100 mg once daily (usual antibacterial dosage) in a small, randomized, double-blind trial. Expand